麻豆传媒

Patients resistant to the loop diuretic furosemide did not find greater decongestive relief in a small trial. (European Heart Journal)

Longer time spent in tracked with better cardiovascular outcomes in people with type 2 diabetes and overweight or obesity. (European Journal of Preventive Cardiology)

Heart failure care tailored to boosted quality of life and reduced heart failure hospitalizations in patients in the Dutch MONITOR-HF trial. (The Lancet)

In a head-to-head trial, after weeks of sacubitril/valsartan (Entresto) therapy versus the angiotensin-receptor blocker alone in recently stabilized heart failure patients with ejection fractions of 40% or more. (Journal of the American College of Cardiology)

Records from the Department of Veterans Affairs showed a mere among eligible patients with atherosclerotic cardiovascular disease, heart failure, and type 2 diabetes. (JACC: Heart Failure)

People with hypertrophic cardiomyopathy did not experience higher rates of mortality or ventricular arrhythmias with in a prospective cohort study. (JAMA Cardiology)

FDA approved the that boast 13 years of use in a compact device, MicroPort CRM said.

Abbott said its was also FDA approved for atrial fibrillation patients.

The was also approved, Abbott added.

An excess and early incidence of heart failure over 5 years was observed in , specifically those treated with anthracycline chemotherapy. (JACC: CardioOncology)

At the Heart Failure congress, the European Society of Cardiology highlighted a finding that may predict a lower risk of heart failure after acute myocardial infarction.

In acute coronary syndrome, produced similar 5-year clinical results when compared with third-generation everolimus-eluting stents, according to a report from EuroPCR that was also published in JAMA Cardiology.

Also presented at the EuroPCR conference were 6-month results supporting blood pressure control with the for selective renal denervation in hypertension, SyMap Medical announced.

New American guidelines for the management of endorse transfer to comprehensive stroke centers and monitoring for delayed cerebral ischemia. (Stroke)

Paragonix Technologies said its SherpaPak kept a donor heart intact over an impressive for transplantation.

showed promise in repressing the PCSK9 gene and reducing LDL cholesterol levels with IV doses delivered to non-human primates, according to Tune Therapeutics.

VTT researchers announced their development of a made of nanocellulose.

Comment